Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. SPY
3. IONS
4. ACN
5. AZN
6. ROIV
7. AAPL
8. HOOD
9. QCOM
10. NVDA

Go back to Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis
(NASDAQ: MCRB) Delayed: 5.72 --0 (-0%)
Previous Close $5.72    52 Week High $44.51 
Open $5.68    52 Week Low $8.05 
Day High $5.75    P/E N/A 
Day Low $5.40    EPS $0.00 
Volume 9,644